Therapeutic Asset Ratings
227 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
ly3023414
Ovarian Cancer
Dana-Farber Cancer Institute
P2
CC
(46)
Tazemetostat
Metastatic Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute
P1/2
CC
(46)
Polyiclc
Ovarian Cancer
Dana-Farber Cancer Institute
P1/2
CC
(44)
Axicabtagene Ciloleucel
Primary Central Nervous System Lymphoma
Dana-Farber Cancer Institute
P1
CC
(43)
Ciml-Nk Cells
Juvenile Myelomonocytic Leukemia
Dana-Farber Cancer Institute
P1
CC
(43)
Cyclophosphamide
Anaplastic Oligodendroglioma
Dana-Farber Cancer Institute
P1
CC
(43)
Cyclophosphamide
Ganglioglioma
Dana-Farber Cancer Institute
P1
CC
(43)
Cyclophosphamide
Glioma of Brain
Dana-Farber Cancer Institute
P1
CC
(43)
Cyclophosphamide
Anaplastic Astrocytoma
Dana-Farber Cancer Institute
P1
CC
(43)
Cyclophosphamide
Brain Glioma
Dana-Farber Cancer Institute
P1
CC
(43)
Cyclophosphamide
Oligoastrocytoma
Dana-Farber Cancer Institute
P1
CC
(43)
Cyclophosphamide
Oligodendroglioma
Dana-Farber Cancer Institute
P1
CC
(43)
Cyclophosphamide
Pilocytic Astrocytoma
Dana-Farber Cancer Institute
P1
CC
(43)
Cytokine Induced Memory-Like Natural Killer Cells
Myeloproliferative Disorders
Dana-Farber Cancer Institute
P1
CC
(43)
Cytokine-Induced Memory-Like Natural Killer Cells
Ovarian Clear Cell Adenocarcinoma
Dana-Farber Cancer Institute
P1
CC
(43)
Cytokine-Induced Memory-Like Natural Killer Cells
Ovarian Endometrioid Adenocarcinoma
Dana-Farber Cancer Institute
P1
CC
(43)
Epirubicin
Leukemia, B-cell
Dana-Farber Cancer Institute
P1
CC
(43)
FULVESTRANT
Acute Lymphoblastic Leukemia ALL
Dana-Farber Cancer Institute
P1
CC
(43)
Mesna
Graft Versus Host Disease
Dana-Farber Cancer Institute
P1
CC
(43)
Mesna
Myeloid Leukemia
Dana-Farber Cancer Institute
P1
CC
(43)
Neovax
Lymphoid Leukemia
Dana-Farber Cancer Institute
P1
CC
(43)
Pembrolizumab
Lymphoid Leukemia
Dana-Farber Cancer Institute
P1
CC
(43)
Polyiclc
Lymphocytic Leukemia
Dana-Farber Cancer Institute
P1
CC
(43)
Recombinant Human Interleukin-2
Myelodysplasia
Dana-Farber Cancer Institute
P1
CC
(43)
Recombinant Human Interleukin-2
Myeloproliferative Disorders
Dana-Farber Cancer Institute
P1
CC
(43)
Showing 126 to 150 of 227 assets
Previous
Page 6 of 10
Next